MedTrace Logo

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

NCT05629338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-09-18

No results posted yet for this study

Summary

This study in healthy volunteers is designed to assess the safety of infusing increasing doses of spray dried plasma (FrontlineODP).

Conditions

Interventions

COMBINATION_PRODUCT

Autologous Spray Dried Plasma

Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers

Sponsors & Collaborators

  • Velico Medical

    lead INDUSTRY

Principal Investigators

  • Mark Popovsky, MD · Velico Medical

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-03-18
Completion
2025-04-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05629338 on ClinicalTrials.gov